BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17634541)

  • 1. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.
    Duncan TJ; Rolland P; Deen S; Scott IV; Liu DT; Spendlove I; Durrant LG
    Clin Cancer Res; 2007 Jul; 13(14):4139-45. PubMed ID: 17634541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Duncan TJ; Al-Attar A; Rolland P; Scott IV; Deen S; Liu DT; Spendlove I; Durrant LG
    Clin Cancer Res; 2008 May; 14(10):3030-5. PubMed ID: 18483368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer.
    Duncan TJ; Al-Attar A; Rolland P; Harper S; Spendlove I; Durrant LG
    Int J Gynecol Pathol; 2010 Jan; 29(1):8-18. PubMed ID: 19952944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
    Rolland P; Deen S; Scott I; Durrant L; Spendlove I
    Clin Cancer Res; 2007 Jun; 13(12):3591-6. PubMed ID: 17575223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma expression is an independent prognostic factor in ovarian cancer.
    Marth C; Fiegl H; Zeimet AG; Müller-Holzner E; Deibl M; Doppler W; Daxenbichler G
    Am J Obstet Gynecol; 2004 Nov; 191(5):1598-605. PubMed ID: 15547530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
    Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
    J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
    Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
    Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
    Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y
    Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
    Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
    Qiao YH; Cheng J; Guo RX
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):325-9. PubMed ID: 17673045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
    Khouja MH; Baekelandt M; Nesland JM; Holm R
    Int J Gynecol Pathol; 2007 Oct; 26(4):418-25. PubMed ID: 17885492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.
    Rosen DG; Yang G; Deavers MT; Malpica A; Kavanagh JJ; Mills GB; Liu J
    Cancer; 2006 May; 106(9):1925-32. PubMed ID: 16568440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
    Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
    Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
    Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.